UNSPSC 51402303: Enpiprazole

This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78G92X9EH7. European Medicines Agency schedules Enpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06544MIG. Enpiprazole generally arises in the molecular formula C16H21CLN4.

UNSPSC 51402303 Enpiprazole is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement. The code's nominal scope—enpiprazole, a specific pharmaceutical compound—bears no relation to the three recent opportunities posted under this code, which instead cover naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code designation and the actual solicitations suggests a tagging error in the source data rather than legitimate market activity for enpiprazole itself. State and local governments appear to have incorrectly indexed these opportunities, making this code unreliable as a signal for enpiprazole demand or for pharmaceutical-procurement strategy in general.

The recent opportunities do reveal scattered activity in pharmaceutical supply and pharmacy benefit management across state health agencies and county health departments. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—a date inconsistency in the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription models for state pharmacy benefits. The Minnesota Department of Administration's MMCAP posted an RFP on January 20, 2026 (due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities across Minnesota and Oregon. These examples span Florida, Texas, and Minnesota, but their presence under this single Commodity code reflects indexing error rather than genuine category coherence. Firms pursuing state and local pharmaceutical contracts should verify code assignments in RFP notices directly rather than relying on this code's current taxonomy mapping.